ESTRO 2025 - Abstract Book

S2110

Clinical - Urology

ESTRO 2025

Conclusion: The results of our experience showed that SBRT in oligometastatic prostate cancer is an effective option with significant survival rates and no severe toxicities. Complete response was associated with OS rates >90% at 3 years.

Keywords: prostate cancer, SBRT, oligometastatic cancer

4223

Digital Poster The relation between quality of life and biomarkers in oligorecurrent prostate cancer: a RADIOSA Clinical Trial (NCT03940235) preliminary analysis. Ketti Mazzocco 1,2 , Giulia Marvaso 3,2 , Chiara Lorubbio 3,2 , Mattia Zaffaroni 3 , Sara Gandini 4 , Cristiana Iuliana Fodor 3 , Sofia Netti 4 , Tiziana Burla 3,1 , Gabriella Pravettoni 2,1 , Ottavio De Cobelli 5 , Barbara Alicja Jereczek-Fossa 3,2 1 Division of Applied Research for Cognitive and Psychological Sciences, IEO European Institute of Oncology IRCCS, Milan, Italy. 2 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 3 Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 4 Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 5 Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy Purpose/Objective: Quality of life (QoL) and Psychological well-being in prostate cancer (PCa) patients are significantly affected by diagnosis and treatments. Little is known about the relation between QoL and prognostic biomarkers in oligorecurrent PCa patients. The RADIOSA phase II clinical trial aims to assess QoL and prognostic biomarkers comparing oligorecurrent PCa patients undergoing Stereotactic body radiotherapy (SBRT) alone treatment with a combination of SBRT and androgen deprivation therapy (ADT). Material/Methods: Patients with up to 3 bone or lymph node lesions were enrolled and randomized 1:1 in two different arms: SBRT alone (ARM A) and SBRT + 6 months ADT (ARM B). Four different inflammation biomarkers were collected at baseline (T0) and 3 months (T1): neutrophil-lymphocyte ratio (NLR), NLR -albumin ratio (NLRAR), platelet-to lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII). Participants filled out three validated questionnaires: (i) the University of California-Los Angeles (UCLA) Prostate Cancer Index (UCLA-PCI), (ii) the SF-36 measures health; (iii) the Impact of Events scale (IES-R). The QoL data here considered were collected at T0 and T1. Preliminary non-parametric Wilcoxon rank-sum tests, linear regression models and network analyses were run to assess the relations between QoL, inflammation status and possible interactions with the type of treatment. Results: Preliminary analyses show no significant differences in the inflammation status of the two arms at T0 for all the considered indexes (N=101; 50 ARM A vs 51 ARM B). No significant correlations were found between QoL scales and biomarkers at T0 and T1. Focusing on ARM A at T1, the network analysis shows associations of several dimensions of QoL with PLR, NLR, albumin level and SII. Furthermore, PLR, NLR and albumin show a strong relation to SII index, suggesting a possible indirect association between QoL and SII in addition to other direct effects. Regarding ARM B at T1, the network analysis shows an inverted association of albumin levels with some dimensions of QoL (Bowel Function (UCLA-BF) and Urinary Function (UCLA-UF).